Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ATBPF NASDAQ:MRKR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATBPFAntibe Therapeutics$0.22$0.22$0.11▼$0.89$11.42M0.5127,352 shsN/AMRKRMarker Therapeutics$1.46+11.0%$1.43$0.81▼$4.07$21.92M1.4453,889 shs98,250 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATBPFAntibe Therapeutics0.00%0.00%0.00%0.00%0.00%MRKRMarker Therapeutics0.00%-1.13%-16.24%+6.05%-9.93%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATBPFAntibe Therapeutics$0.22$0.22$0.11▼$0.89$11.42M0.5127,352 shsN/AMRKRMarker Therapeutics$1.46+11.0%$1.43$0.81▼$4.07$21.92M1.4453,889 shs98,250 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATBPFAntibe Therapeutics0.00%0.00%0.00%0.00%0.00%MRKRMarker Therapeutics0.00%-1.13%-16.24%+6.05%-9.93%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATBPFAntibe Therapeutics 0.00N/AN/AN/AMRKRMarker Therapeutics 2.25Hold$10.00584.93% UpsideCurrent Analyst Ratings BreakdownLatest ATBPF and MRKR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026MRKRMarker Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/20/2026MRKRMarker Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 6/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATBPFAntibe TherapeuticsN/AN/AN/AN/A$0.58 per shareN/AMRKRMarker Therapeutics$3.55M6.86N/AN/A$1.01 per share1.45Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATBPFAntibe Therapeutics-$14.73M-$0.25N/AN/AN/AN/A-56.48%-29.07%N/AMRKRMarker Therapeutics-$12.16M-$0.61N/AN/AN/A-343.03%-73.29%-59.70%8/13/2026 (Estimated)Latest ATBPF and MRKR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026MRKRMarker Therapeutics-$0.18-$0.16+$0.02-$0.16$0.78 million$0.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATBPFAntibe TherapeuticsN/AN/AN/AN/AN/AMRKRMarker TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATBPFAntibe TherapeuticsN/A10.0610.06MRKRMarker TherapeuticsN/A4.794.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATBPFAntibe TherapeuticsN/AMRKRMarker Therapeutics22.39%Insider OwnershipCompanyInsider OwnershipATBPFAntibe Therapeutics9.00%MRKRMarker Therapeutics5.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATBPFAntibe Therapeutics1152.98 million48.24 millionNot OptionableMRKRMarker Therapeutics6016.67 million15.72 millionNot OptionableATBPF and MRKR HeadlinesRecent News About These CompaniesZacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and MarkerJune 26 at 6:01 AM | zacks.com5 Small Drug Stocks to Invest in Amid a Biotech ComebackJune 25, 2026 | zacks.comMARKER THERAPEUTICS (MRKR) Upgraded to Buy: What Does It Mean for the Stock?May 20, 2026 | zacks.comMarker Therapeutics Sets Date for 2026 Annual MeetingMay 19, 2026 | theglobeandmail.comMarker Therapeutics (MRKR) price target decreased by 12.83% to 8.02April 9, 2026 | msn.comMARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue EstimatesMarch 18, 2026 | zacks.comMarker Therapeutics Reports Encouraging Phase 1 APOLLO Data and Corporate Developments in Immuno-OncologyMarch 18, 2026 | quiverquant.comQMarker Therapeutics Reports Year-End 2025 Corporate and Financial ResultsMarch 18, 2026 | globenewswire.comMarker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceFebruary 18, 2026 | globenewswire.comGood Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell TechnologyJanuary 26, 2026 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Marker Therapeutics (MRKR), Pasithea Therapeutics Corp (KTTA) and TransMedics Group (TMDX)January 22, 2026 | theglobeandmail.comMRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to KnowJanuary 21, 2026 | zacks.comMarker Therapeutics, Inc. Common Stock (MRKR)January 9, 2026 | nasdaq.comMARKER THERAPEUTICS, INC. (MRKR) Now Trades Above Golden Cross: Time to Buy?January 7, 2026 | zacks.com5 Small Drug Stocks to Buy as Industry Recovery Picks UpJanuary 7, 2026 | zacks.comMarker Therapeutics announces publication on MAR-T cells in pancreatic cancerJanuary 5, 2026 | msn.comBaylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic CancerJanuary 5, 2026 | globenewswire.comHere's Why Marker Therapeutics (NASDAQ:MRKR) Must Use Its Cash WiselyDecember 18, 2025 | finance.yahoo.comHC Wainwright & Co. initiates coverage of Marker Therapeutics (MRKR) with buy recommendationDecember 8, 2025 | msn.comMarker Therapeutics initiated with a buy at HC WainwrightDecember 8, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATBPF and MRKR Company DescriptionsAntibe Therapeutics OTCMKTS:ATBPF$0.22 0.00 (0.00%) As of 06/26/2026Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.Marker Therapeutics NASDAQ:MRKR$1.46 +0.15 (+11.03%) Closing price 04:00 PM EasternExtended Trading$1.44 -0.02 (-1.71%) As of 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The AI Boom Has a Second Act—And It's Playing Out in Optics Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback? 5 Tech Stocks to Buy on the July Pullback Is OpenAI’s IPO Delay a Warning for AI Investors? onsemi: What the Market Gets Wrong, You Can Get Right 5 Places Investors Can Hide If the AI Trade Keeps Cracking MarketBeat Week in Review – 06/22 - 06/26 Qualcomm’s Investor Day Just Changed the Growth Story Forever Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
